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Kaposi’s sarcoma-associated herpesvirus (KSHV) open reading frame K8 encodes a basic region-leucine
zipper protein of 237 amino acids that homodimerizes with its bZIP domain. KSHV K8 shows significant
homology to the Epstein-Barr virus (EBV) immediate-early protein Zta, a key regulator in the reactivation and
replication of EBV. In this study, we report that K8, like its homolog EBV Zta, interacts with cellular
CREB-binding protein (CBP) in vivo and in vitro. This interaction requires the C/H3 domain of CBP and the
basic region of K8. K8 represses CBP-mediated transcription by competing with limited amounts of cellular
CBP, exemplified by the reduced expression from the AP-1 and human immunodeficiency virus long terminal
repeat promoters.
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) is a
recently discovered human gamma herpesvirus, and it is the
eighth type of human herpesvirus (HHV8) (8, 36, 37). KSHV
has been identified as an important pathogen in KS (8). KSHV
is also associated with abnormal lymphoproliferation. In a
KSHV infection, the viral DNA is found principally in B cells
and in spindle cells (7). The most important step in the KSHV
life cycle may be the switch from latency to lytic replication,
and viral lytic replication is important in KS development (7,
31, 37). Upon chemical induction with tetradecanoyl phorbol
ester acetate (TPA) or sodium butyrate, KSHV produces im-
mediate-early viral transcripts. These transcripts encode viral
transcriptional activator proteins, such as open reading frame
(ORF) 50, which is necessary for inducing the lytic phase of
KSHV (29, 30, 38, 43).
KSHV ORF K8 encodes an early viral protein that is acti-
vated by and expressed after KSHV ORF 50 protein (28, 39).
It is a homodimerizing protein of 237 amino acids with a
prototypic basic region-leucine zipper (bZIP) domain at the
carboxyl terminus by in-frame splicing (28). K8 shows signifi-
cant homology to the Epstein-Barr virus (EBV) immediate-
early gene product Zta (also called ZEBRA, EB1, and
BZLF1) (16, 28). The EBV Zta protein is a well-known bZIP
family transcriptional activator, which induces the entire lytic
cycle of EBV (26, 31). Zta binds to the amino-terminal region
of CREB-binding protein (CBP) and interacts with CBP. This
interaction enhances Zta-mediated transactivation of EBV
early promoters. It also controls host cellular transcription
factor activity through competition by limiting the amount of
cellular CBP (1, 42).
CBP, initially known as a coactivator for the transcription
factor CREB (24), functions in a variety of signaling pathways
and modulates specific gene expression (14, 20). The ability of
CBP to interact with multiple, signal-dependent transcription
factors, including Jun, Fos, and NF-B (5, 21, 34), suggests that
this coactivator functions as a signal integrator by coordinating
complex signal transduction events at the transcriptional level
(4, 21). CBP also mediates transcriptional activation via intrin-
sic and associated histone acetyltransferase (HAT) activities
and targets gene activation through association with active
RNA polymerase II complex (14, 23, 25).
Here, we show that K8 interacts and colocalizes with CBP.
CBP is immunoprecipitated with anti-K8 antibodies in
BCBL-1 cell lines, which contain KSHV DNA. K8 binds to the
C/H3 domain of CBP, which is known as the interacting do-
main of adenovirus E1A proteins (3, 9). The interacting do-
main of K8 with CBP locates within the basic region of K8. K8
represses the CBP-mediated transcription activities of AP-1
and the human immunodeficiency virus (HIV) long terminal
repeat (LTR) promoters. Deletion mutants of K8 which had
lost their binding activity to CBP did not repress the transcrip-
tional activities of these promoters, and CBP was able to re-
lieve the K8-mediated repression in a dose-dependent manner.
CBP has been shown to associate with the promyelocytic leu-
kemia (PML) protein and to be recruited to the PML onco-
genic domains (PODs) (10, 11, 25). The fact that K8 interacts
with CBP also coincides with the recent data indicating that K8
localizes in the PODs, in which a fraction of CBP is recruited
(41).
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K8 interacts with CBP in vivo. In order to clone the full-
length cDNA of K8, we performed a reverse transcription-
PCR (RT-PCR) using the appropriate primers on poly(A)
RNAs from BCBL-1 cell lines treated with TPA (20 ng/ml) for
48 h. We verified the resulting clone by sequencing and com-
paring it with the cDNA sequence of K8 in GenBank (acces-
sion no. AF072866) (28). 293T cells were transfected in the
following ways: (i) with no DNA (Mock) and 7 g of a hem-
agglutinin (HA)-tagged CBP expression vector (HA-CBP) in
the presence or absence of a blank (as a negative control;
pEBG; a gift from J. Jung) vector and(ii) a glutathione S-
transferase (GST)-fused K8 expression plasmid (pEBG-K8;
K8 cloned into the BamHI and NotI sites of pEBG) using the
calcium phosphate precipitation method (15). Forty-eight
hours after transfection, the cells were harvested and lysed in
binding buffer (20 mM HEPES [pH 7.4], 100 mM NaCl, 1%
Triton X-100, 0.5% NP-40 supplemented with protease inhib-
itors). The cell lysates were mixed in the buffer for 1 h at 4°C
before the cell debris was removed by centrifugation. The
appropriate lysates were immunoprecipitated with the addition
of antibodies against HA (-HA) or GST (-GST) and a
protein G resin (Santa Cruz Biotechnology, Santa Cruz, Cal-
if.). The beads were washed four times, and the proteins were
analyzed by 7 and 12% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). They were transferred to a
nitrocellulose membrane, immunoblotted with anti-HA or an-
ti-GST antibodies, and visualized with an enhanced chemilu-
minescence reagent according to the manufacturer’s instruc-
tions (Amersham Pharmacia Biotech, Uppsala, Sweden). As
shown in Fig. 1A, the anti-GST antibody immunoprecipitated
GST and GST-fused K8 specifically and coimmunoprecipi-
tated CBP from the cell extract that was cotransfected with K8,
but not from the cell extracts transfected with the blank vector.
The above results confirm that K8 binds to CBP in vivo.
To confirm this interaction in the physiological condition, we
performed a coimmunoprecipitation assay in the KSHV-posi-
tive BCBL-1 cell line (Fig. 1B). The B-cell lymphoma BJAB
cell lines were used as a KSHV-negative control. BCBL-1 cells
with or without TPA induction (48 h) were harvested, and the
appropriate lysates were precipitated with either mouse CBP-
specific monoclonal antibody (-CBP; Santa Cruz Biotechnol-
ogy) or rabbit polyclonal anti-K8 antibody (-K8). K8 was
specifically detected in the BCBL-1 cells 48 h after TPA in-
duction. Anti-K8 antibody coimmunoprecipitated CBP from
the TPA-induced BCBL-1 cell lines, but not from BJAB or
uninduced BCBL-1 cell lines. These results showed that K8
binds to CBP in KSHV-positive cell lines.
K8 colocalizes with CBP. We next assessed whether or not
K8 and CBP were colocalized in 293T cells. Green fluorescent
protein (GFP)-tagged K8 (GFP-K8; K8 cloned into the EcoRI
and XhoI sites of pEGFP-C1; Clontech, Palo Alto, Calif.) and
HA-CBP were transfected into 293T cells. Forty-eight hours
after transfection, the cells were fixed with 3.7% formaldehyde,
permeabilized with 0.2% Triton X-100, and immunostained.
HA-CBP was detected using a rhodamine-conjugated second-
ary antibody against a mouse monoclonal HA antibody (Santa
Cruz Biotechnology). Imaging was performed using a confocal
microscope equipped with an argon-krypton laser (LSM510;
Zeiss, Oberkochen, Germany). GFP alone showed a diffuse
pattern throughout the cytoplasm and nucleus (data not
shown). As shown in Fig. 1C, K8 was located mainly in the
nucleus (22). Cotransfection of HA-CBP with GFP-K8 yielded
a yellow color indicative of colocalization in the nucleus.
To examine the colocalization of K8 and CBP in physiolog-
ical conditions, we performed confocal microscopy in the TPA-
induced BCBL-1 cell. Forty-eight hours after TPA induction,
BCBL-1 cells were immunostained and attached to poly-L-
lysine-coated glass slide. K8 was detected by indirect immuno-
fluorescence using a rabbit anti-K8 antibody (-K8) as primary
antibody and a fluorescein isothiocyanate (FITC)-conjugated
goat anti-rabbit immunoglobulin G (IgG) as the secondary
antibody. CBP was detected with a mouse CBP-specific
monoclonal antibody (-CBP) and a tetramethylrhodamine
isothiocyanate (TRITC)-conjugated goat anti-mouse IgG.
The nucleus of the cell was stained with 4,6-diamidino-2-
phenylindole (DAPI; Sigma, St. Louis, Mo.). As shown in
Fig. 1D, K8 shows a nuclear punctate pattern within nuclear
background (41) and colocalizes with CBP in TPA-induced
BCBL-1 cells.
K8 binds to the C/H3 domain of CBP. To determine the
K8-binding domain of CBP, we performed GST pulldown as-
says with in vitro-translated K8 and deletion mutants of CBP
fused to GST (Fig. 2A). CBP consists of the KIX, the HAT, the
zinc finger motifs, and the carboxyl-terminal transcriptional
activation domain (TAD) (17, 18, 24, 40). The CBP fragments
were subcloned into pGEX4T-1 (Amersham Pharmacia Bio-
tech). The GST-CBP fusion proteins were expressed and pu-
rified according to the manufacturer’s instructions. K8 was in
vitro transcribed and translated using a T7-coupled transcrip-
tion-translation system (Promega, Madison, Wis.). The 35S-
labeled K8 proteins were incubated with 1 g of a GST-fused
CBP fragment in binding buffer (20 mM HEPES [pH 7.4], 100
mM NaCl, 0.5% NP-40 supplemented with protease inhibi-
tors). Glutathione-Sepharose 4B (Amersham Pharmacia Bio-
tech) beads were then added, and the reaction mixture was
incubated at 4°C overnight. The beads were then washed four
times with the binding buffer. The proteins were analyzed by
SDS–12% PAGE and visualized by autoradiography on a Fujix
BAS-1500 (Fuji Film Co., Tokyo, Japan). In vitro-translated
K8 did not bind to GST alone or to other GST-fused CBP
deletion mutants except a CBP2 fragment, which contains the
C/H3 conserved region (Fig. 2B). The adenovirus E1A protein
also binds to the C/H3 region of CBP (3).
Basic domain of K8 is responsible for association with
CBP2 domain. To determine the CBP-binding domain of K8,
we performed GST pulldown assays using in vitro-translated
CBP2 and GST-fused K8 and deletion mutants (Fig. 2C).
Amino acids 1 to 158 of K8 are derived from exon 1 and 159
to 189 are from exon 2. The basic region of K8 is amino acids
116 to 189, which is derived from part of exon 1 (116 to 158)
and exon 2 (159 to 189). This basic region of K8 is necessary for
binding to CBP, because mutants which have a part of the basic
region [K8(159–237) and K8(1–158)], bind to CBP2 (Fig. 2D,
lanes 7 and 10), but K8(190–237) and K8(1–115) mutants,
which do not contain the basic region, do not bind to CBP2
(Fig. 2D, lanes 8 and 11). It is also shown that the part of the
basic region, amino acids 116 to 158 or 159 to 189, is sufficient
for binding to CBP (Fig. 2D, lanes 14 and 15). The HIV Tat
protein also interacts with CBP through its basic domains (19).
Because many basic region-leucine zipper (bZIP) proteins
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dimerize by using the ZIP domain and K8 also homodimerizes
with its leucine zipper domain (16, 28), we next assessed
whether the leucine zipper region is required for binding to
CBP when K8 is not in the form of a GST fusion protein. GST
pulldown assays of in vitro-translated K8 and K8(1–189), which
does not contain a Zip domain, with GST-K8 and GST-CBP2
clearly showed that a Zip domain is necessary for the ho-
modimerization of K8, but not for binding to CBP (Fig. 2E).
FIG. 1. In vivo interaction of K8 and CBP. (A) The coimmunoprecipitation of in vivo-synthesized K8 and CBP was analyzed by Western
blotting. 293T cells were transfected with an HA-tagged CBP expression vector and either a blank (pEBG) vector or an expression vector carrying
GST-fused K8 (pEBG-K8). The cells were harvested, lysed, and precipitated with either anti-HA antibody (-HA) or anti-GST antibody (-GST),
and protein G resin. The proteins were analyzed by SDS-PAGE and immunoblotted with anti-HA or anti-GST antibodies. (B) Coimmunopre-
cipitation assay in the KSHV-positive BCBL-1 cell lines. The BJAB cell lines were used as a KSHV-negative control. BCBL-1 cell lines, with or
without TPA induction (48 h), were harvested, and the appropriate lysates were precipitated and immunoblotted with either CBP-specific
monoclonal antibody (-CBP) or rabbit polyclonal anti-K8 antibody (-K8), respectively. (C) K8 colocalizes with CBP in 293T cells. The GFP-K8
and HA-CBP expression vectors were transfected into 293T cells. Cells were fixed and immunostained 48 h after transfection. HA-CBP was
detected using a rhodamine-conjugated secondary antibody against a mouse monoclonal HA antibody. (D) Colocalization of K8 and CBP in
BCBL-1 cells. For the expression of lytic gene product K8, BCBL-1 cells were treated with TPA for 48 h. K8 was detected by indirect
immunofluorescence using a rabbit anti-K8 antibody as a primary antibody and FITC-conjugated goat anti-rabbit IgG as a secondary antibody.
CBP was detected with a mouse CBP-specific monoclonal antibody and TRITC-conjugated goat anti-mouse IgG. The nucleus of the cell was
stained with DAPI.
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FIG. 2. In vitro interaction and the interacting domains of K8 with CBP. (A) The domains of CBP and the GST-fused CBP fragments are
indicated. KIX, kinase-induced domain interacting domain; ZF, zinc finger; CTAD, carboxyl-terminal transcriptional activation domain. (B) GST
pulldown assays with in vitro-translated, 35S-labeled K8 and deletion mutants of CBP fused to GST. (C) Domains within K8 and the deletion
mutants. The K8 fragments were introduced into pGEX4T-1. (D) GST pulldown assays were performed with in vitro-translated, 35S-labeled CBP2
and GST-fused K8 fragments. (E) GST pulldown assays of in vitro-translated K8 and its mutant K8(1–189) with GST-fused K8 and CBP2. (F)
Localization of K8 deletion mutants was investigated by immunostaining 293T cells transfected with each Flag-tagged K8 deletion mutant. (G)
Localization of K8 and NLS-deleted mutants K8(190–237) and K8(1–115) cloned into an NLS-containing CMV2N3T vector.
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NLS of K8 is within the basic region derived from exon 1.
Subcellular localization of K8 deletion mutants was tested be-
fore the mutants was compared to wild-type K8. Wild-type K8
and deletion mutants were cloned into the EcoRI and XhoI
sites of pFLAG-CMV-2 (Kodak, Rochester, N.Y.) and trans-
fected into 293T cells. Forty-eight hours after transfection, the
cells were fixed, immunostained, and detected using a rhodam-
ine-conjugated secondary antibody against a mouse monoclo-
nal Flag antibody (Sigma). While the wild-type K8 localizes
only in the nucleus (22, 35), deletion mutants without amino
acids 116 to 158 [K8(159–237) and K8(1–115)] localize in the
cytoplasm (Fig. 2F). Another deletion mutant that has only
amino acids 116 to 158 [K8(116–158)], localizes in the nucleus,
as does the wild-type K8. This finding suggests that the nuclear
localization signal (NLS) of K8 is within amino acids 116 to
158. This putative NLS designation is further supported and
specified by the PSORT WWW server (Kenta Nakai and Paul
Horton, http://psort.ims.u-tokyo.ac.jp/). Data on this server in-
dicate that the NLS of K8 is PTRRSKR, which is located at
amino acids 123 to 129. This result is similar to the NLS of
simian virus 40 large T antigen. It also corresponds to the short
amino acid sequence TRRSKRRLHRKF between residues
124 and 135, which was identified by Portes-Sentis et al. (35).
These data suggest that the NLS in a basic region (amino acids
116 to 158) is essential for the localization of K8 in the nucleus.
Therefore, we cloned the K8 and deletion mutants into the
EcoRI and XbaI sites of a CMV2N3T vector, which fuses NLS
and HA tag into the amino-terminal region of a cloned protein
(a gift from D. Trouche). This confirmed that all CMV2N3T
clones were localized in the nucleus (Fig. 2G).
K8 represses transcription from AP-1 and HIV LTR in a
CBP-dependent manner. CBP is an integrator of multiple sig-
nal transduction pathways (4, 14, 20, 21). A variety of inducible
genes have multiple elements for transcription factors that
bind to CBP, such as AP-1 (5, 21) and HIV LTR promoters
(23, 33, 34). To investigate whether the interaction of K8 and
CBP has an effect on the physiological condition of cells or the
viral life cycle, we tested the effect of K8 and its CBP-binding-
deficient mutants on the above promoters in a transient re-
porter assay. We performed transient reporter assays in which
293T and BJAB cells were transiently cotransfected with a
reporter and one or more of the expression vectors. BJAB cells
were transfected by electroporation as described previously
(30). In Fig. 3A, a reporter gene, AP-1 luciferase (Luc)
(p3XAP1-tk-Luc, containing artificial AP-1-responsive ele-
ments, a gift from Y. Nagamine) and K8 expression plasmids
CMV2N3T K8, K8(190–237), and K8(1–115) were transfected
and assayed. The amounts of the expression plasmids are in-
dicated in the figure. The total amounts of the expression
vectors were kept constant by adding an empty cytomegalovi-
rus (CMV) expression plasmid. K8 repressed the transcription
of the AP-1 reporter with or without TPA induction, but the
CBP-binding-deficient mutants did not affect the transcription
of the AP-1 reporter. In Fig. 3B, pcDNA3/c-Fos (cloned into
the EcoRI and XhoI sites of pcDNA3; Invitrogen, Carlsbad,
Calif.) expression plasmid was used to activate the AP-1 pro-
moter instead of TPA. K8 also represses c-Fos activity in a
CBP-binding-dependent manner. To prove that the repression
by K8 is due to the reduction in the limited amount of coac-
tivator CBP available for transcriptional activation, we tested
whether the repression by K8 can be overcome by addition of
CBP. We found that CBP was able to relieve the K8-mediated
repression of AP-1 promoter in a dose-dependent manner
(Fig. 3C).
To provide further support for the CBP-dependent repres-
sion of AP-1 by K8 in physiological conditions, BJAB cells
were transiently cotransfected with the same reporter plasmid
and expression vectors, and similar results were observed (Fig.
3D). In all assays, the fold activation was determined by lucif-
erase activity derived from the reporter after normalizing it to
-galactosidase (Gal) activity from a cotransfected Rous sar-
coma virus (RSV) -Gal control plasmid. All experiments were
performed at least in triplicate, and the equivalent expression
of each plasmid was verified by Western blotting (data not
shown). The Luc activity of AP-1, in the absence of TPA or
c-Fos induction and the other expression vectors, is normalized
to a value of 1. Gene expression from AP-1 is regulated by a
combination of the various AP-1 activators, such as c-Fos and
c-Jun. Enhancement of transcription by AP-1 protein requires
the presence of an additional mediator protein, CBP (5, 21).
Because AP-1 requires relatively low intracellular levels of the
CBP, the interaction of CBP with K8 correlates with the K8
activity to repress TPA- or c-Fos-mediated AP-1 promoter
activation, similar to that of adenovirus E1A (5). The loss of
CBP binding correlates with a loss of the repression activity of
the K8 deletion mutants.
We next investigated the effect of CBP competition by K8 on
another well-known viral promoter, HIV LTR. Transcriptional
activation of HIV LTR is highly responsive to the transcription
factor nuclear factor-B (NF-B) (20, 33). The binding of
NF-B to CBP is critical for NF-B activity (13, 14, 34). CBP
potentially influences the activation of HIV gene expression
through its effects on NF-B transactivation (34). 293T cells
were transiently cotransfected with an HIV LTR reporter gene
(pLTRluc-wt, containing a 186-bp fragment of the HIV-1 LAI
strain 5 LTR; a gift from M. Benkirane) and the indicated
amounts of expression vectors. The Luc activity of pLTRluc-wt
in the absence of the other expression vectors is normalized to
a value of 1. Functioning similarly to the AP-1 promoter, the
basal transcription from the HIV LTR was repressed in a
dose-dependent manner by K8 but not by CBP-binding-defi-
cient mutants (Fig. 4A). CBP relieved the repression of HIV
LTR by K8 in a dose-dependent manner (Fig. 4B), and the
same amount of CBP did not activate the HIV LTR promoter.
BJAB cells were transiently cotransfected with the same re-
porter plasmid and expression vectors in the indicated
amounts, and similar results were observed (Fig. 4C). Equiv-
alent expression of each plasmid was verified by Western blot-
ting with anti-HA antibody (Fig. 4D).
As shown in Fig. 3 and 4, K8 repressed the transcription of
the AP-1 and HIV LTR promoters, but the deletion mutants
K8(190–237) and K8(1–115), which do not bind to CBP, did
not repress the transcription as effectively as wild-type K8.
Since CBP is physiologically maintained at a limiting concen-
tration (21), K8 then has the capacity to modulate AP-1- and
NF-B-responsive elements that contain promoters such as
AP-1 and HIV LTR. K8 may inhibit transcription of other
promoters through the interaction with CBP. This suggests
that K8 interferes with CBP to function as a transcriptional
coactivator, as does adenovirus E1A (4). Recent data showed
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that K8 interacts directly with p53 and represses p53-mediated
transcriptional activity (32). Transcriptional activation by p53
was reported to be dependent on CBP. E1A represses p53-
mediated transcription by competitively inhibiting the interac-
tion of CBP with p53 (17, 27). Thus, it is possible that K8
represses the p53-mediated transactivation indirectly by the
inhibition of p53 binding to CBP, as well as by direct interac-
tion with p53.
Wu et al. (41) showed the association and colocalization of
K8 with the KSHV pseudo-replication compartment structure
and PML protein in PODs. This suggests another possibility,
that K8 plays an important role in KSHV replication. Several
data showed the function of PML in viral propagation, such as
interferon-induced upregulation, association with viral replica-
tion, and modification of the transcriptional activities of cellu-
lar factors (2, 6, 10, 11, 25, 41). Like other herpesviruses, such
as herpes simplex virus 1 (HSV-1) and human cytomegalovirus
(HCMV), EBV disrupts POD upon lytic reactivation. EBV
Zta can disrupt PML bodies by competing with PML for an
essential small ubiquitin-related modifier-1 (SUMO-1) (2, 6).
Meanwhile, KSHV did not show any loss of PML or disruption
of PODs upon lytic replication (41). K8 associates with PML
but does not disrupt PML. CBP has been shown to associate
with the PML protein and to be recruited to the PODs (10, 11,
25). Recruitment of CBP to the PODs by PML might represent
a critical regulatory step in transcriptional activation (10). It is
possible that K8 can colocalize with PML in PODs and then
modulate the PML activity on viral replication and transcrip-
tion through the interaction with CBP.
CBP functions as a coactivator for several cellular transcrip-
FIG. 3. K8 represses the transcription of AP-1 in a CBP-dependent manner. (A) Transient reporter assays were performed in which 293T cells
were transiently cotransfected with a reporter gene construct (AP-1 Luc) and K8 expression plasmids CMV2N3T K8, K8(190–237), and K8(1–115).
The amounts of expression vectors are shown. In all assays, the fold activation was determined by luciferase activity derived from the reporter after
normalizing it to -Gal activity from a cotransfected RSV -Gal control plasmid. All experiments were performed at least in triplicate, and the
total amount of each expression vector was kept constant. The luciferase activity of AP-1 in the absence of the other expression vectors and TPA
induction is normalized to a value of 1. (B) AP-1 reporter assays with induction by c-Fos expression vector instead of TPA. (C) CBP relieves the
repression of AP-1 by K8 in a dose-dependent manner, but does not activate the AP-1 promoter. (D) Transient reporter assay with the same
reporter and expression vectors in BJAB cell lines.
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tion factors and is also used by viral proteins, such as adeno-
virus E1A and simian virus 40 T antigen, to promote viral gene
transactivation (3, 9, 12). In this study, we showed that KSHV
K8 protein interacts with CBP in vivo and in vitro. This inter-
action needs a basic region of K8 and the C/H3 region of CBP.
It may alter the physiological condition of cells by competing
for limited amounts of CBP, which is exemplified by the re-
pression of gene expression from the AP-1 and HIV LTR
promoter. K8 may also contribute to viral replication and tran-
scription by association with PML that is mediated by CBP.
Previously, we demonstrated that KSHV immediate-early tran-
script ORF 50 protein binds to CBP/p300 and modulates the
transcriptional activities of the cellular transcription factors
through interaction with CBP (18). K8, which is activated by
and expressed after ORF 50 protein, may have a synergistic
role with ORF 50 protein in changing the physiological condi-
tion of cells for propagation of KSHV.
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